Outbreak of pulmonary diseases linked to vaping
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l5445 (Published 10 September 2019) Cite this as: BMJ 2019;366:l5445- David Hammond, professor
- School of Public Health and Health Systems, University of Waterloo, Canada
- david.hammond{at}uwaterloo.ca
Over the past two months, vaping has been associated with more than 450 cases of severe pulmonary disease in the United States. Cases have been detected in 30 US states, including several deaths.1 Primary clinical features include respiratory symptoms such as cough, shortness of breath, or chest pain. Some cases also include gastrointestinal symptoms (nausea, vomiting, or diarrhoea), as well as non-specific constitutional symptoms (fatigue, fever, or weight loss). All cases reported using e-cigarettes before the onset of symptoms.
The outbreak has caused alarm among public health authorities, and renewed questions about the safety of vaping. To date, much of the literature on the health effects of vaping has focused on the relative risk compared with smoking.2 There is now strong consensus that vaping is substantially less harmful than smoking, and smokers who switch exclusively to vaping have the potential to …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.